Pfizer announced last night that it had discontinued research on its most important experimental drug, a treatment for heart disease. The decision is a stunning development that is likely to seriously damage the company’s prospects through the next decade
The news came to Pfizer’s chief scientist, Dr. John L. LaMattina, as he was showering at 7 a.m. Saturday: the company’s most promising experimental drug, intended to treat heart disease, actually caused an increase in deaths and heart problems. Eighty-two
A programme which encouraged women not to diet but to take part in exercise classes found significant improvements in health and mental well-being.
What do steak, tofu and sushi have to do with cancer? Plenty, it seems, if several new studies served up at the American Association for Cancer Research in Boston are to be believed. And not all bear good news: the latest report from the sprawling Nurse's
報主登入
